ΒΆ Docosahexaenoic Acid
ΒΆ Definition
Docosahexaenoic acid (DHA, 22:6n-3) is a 22-carbon omega-3 polyunsaturated fatty acid with six double bonds that serves as both a structural membrane component and a precursor for specialized pro-resolving mediators (SPMs). DHA is the most abundant polyunsaturated fatty acid in neuronal membranes and retinal photoreceptors, comprising 40% of all PUFAs in the brain. It is essential for neurological development, synaptic function, membrane fluidity, and active inflammation resolution via D-series resolvins, protectins, and maresins.
ΒΆ Picture It
Think of DHA as a master builder who works in two completely different jobs at the same construction site. Job 1: Structural Engineer β DHA is woven into the walls of brain cells like flexible steel cables in a suspension bridge, allowing the structure to bend and adapt without breaking. These cables (DHA molecules in membrane phospholipids) make cell membranes fluid and responsive, like a trampoline surface that can receive signals efficiently. In the brain, this flexibility is critical β rigid membranes are like frozen lakes where nothing can move; fluid DHA-rich membranes are like flowing rivers where neurotransmitter receptors can drift into position and signals can propagate.
Job 2: Emergency Response Coordinator β When inflammation strikes (tissue damage, infection), DHA doesn't just sit in the walls. It's released from membranes and transformed by 15-lipoxygenase into a team of resolution specialists: D-series resolvins, protectins, and maresins. These molecules are like fire marshals who arrive after the fire trucks have put out the flames β they clear debris (promote efferocytosis), repair damage, calm overactive immune cells, and restore tissue function. Without DHA, inflammation is like a construction site after a storm with no cleanup crew: the initial damage is contained, but the mess never gets resolved, leading to chronic low-grade inflammation.
The twist: Western diets are deficient in DHA (average intake ~100 mg/day versus recommended 250-500 mg/day), meaning most people have rickety bridges (poor neuronal membrane function) and no cleanup crew (impaired inflammation resolution).
ΒΆ Mechanism
ΒΆ Dietary Absorption and Tissue Incorporation
DHA is obtained from:
- Direct dietary sources: Cold-water fish (salmon, mackerel, sardines), algal oil (vegetarian source)
- Endogenous synthesis (inefficient): Alpha-linolenic acid (ALA, 18:3n-3) β 18:4n-3 β 20:4n-3 β EPA (20:5n-3) β 22:5n-3 β 24:5n-3 β 24:6n-3 β DHA (22:6n-3) via delta-6 desaturase, elongase, delta-5 desaturase, and peroxisomal Ξ²-oxidation. Conversion efficiency is <1% in humans due to rate-limiting delta-6 desaturase enzyme and competition from linoleic acid.
After intestinal absorption, DHA is incorporated into chylomicrons β delivered to tissues β incorporated into membrane phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine) via acyl-CoA synthetase and lysophospholipid acyltransferases.
Blood-brain barrier transport: DHA crosses the BBB via MFSD2A (major facilitator superfamily domain-containing 2A) transporter in the form of lysophosphatidylcholine-DHA (LPC-DHA). MFSD2A is expressed on endothelial cells lining brain capillaries and is essential for neurodevelopment β knockout mice show severe microcephaly and cognitive deficits.
ΒΆ Structural Role in Membranes
DHA's six double bonds create sharp kinks in the fatty acid chain β membranes become highly fluid and flexible:
- Lipid raft formation: DHA-rich domains segregate within membranes, concentrating signaling receptors (e.g., GPR109A, CB1 receptor, NMDA receptor)
- Membrane fluidity: DHA displaces arachidonic acid (AA, 20:4n-6) from phospholipids, reducing pro-inflammatory eicosanoid production
- Receptor function: DHA modulates G-protein coupled receptors (GPCRs), ion channels, and receptor tyrosine kinases by altering membrane microviscosity
- Synaptic plasticity: DHA-enriched synaptic membranes support neurotransmitter release, receptor insertion, and long-term potentiation
ΒΆ Conversion to Specialized Pro-Resolving Mediators (SPMs)
During inflammation, DHA is released from membranes by phospholipase A2 (PLA2) and enzymatically converted to SPMs:
D-series Resolvins (RvD1-6):
- Biosynthesis: DHA β 15-LOX β 17S-hydroperoxy-DHA (17-HpDHA) β 17S-hydroxy-DHA β RvD1-6
- Receptors: RvD1 binds ALX-FPR2 and GPR32; RvD2 binds GPR18 (DRV2 receptor)
- Actions: Inhibit neutrophil infiltration, enhance macrophage efferocytosis, reduce NF-ΞΊB signaling, increase IL-10 production, promote tissue repair
Protectins (PD1/Neuroprotectin D1):
- Biosynthesis: DHA β 15-LOX β 16(17)-epoxide intermediate β PD1 (10R,17S-dihydroxy-DHA)
- Receptors: GPR37 (neuronal receptor)
- Actions: Neuroprotection, reduce oxidative stress, inhibit apoptosis (β Bax, β Bcl-2), suppress COX-2 expression, promote neuroplasticity
Maresins (MaR1-2):
- Biosynthesis: DHA β 12-LOX β 14-hydroperoxy-DHA (14-HpDHA) β 13(14)-epoxide β MaR1 (7R,14S-dihydroxy-DHA)
- Receptors: LGR6 (leucine-rich repeat-containing GPCR 6), ROR-Ξ± (nuclear receptor)
- Actions: Enhance phagocytosis of apoptotic cells, tissue regeneration, reduce pain hypersensitivity, promote wound healing
Aspirin-triggered resolvins: Aspirin acetylates COX-2 β modified enzyme produces 17R-HpDHA (instead of 17S) β AT-RvD1, AT-RvD3 with similar but distinct bioactivity.
ΒΆ DHA and BDNF Signaling
DHA increases brain-derived neurotrophic factor (BDNF) expression via multiple pathways:
- CREB activation: DHA β β phosphorylation of CREB β β BDNF gene transcription
- Epigenetic regulation: DHA promotes histone acetylation at BDNF promoter regions (via β Akt pathway, β histone deacetylases)
- mTOR activation: DHA β mTORC1 β β protein synthesis including BDNF
BDNF β TrkA receptor β neurogenesis, synaptic plasticity, cognitive function, neuroprotection against depression and Alzheimer's Disease.
ΒΆ DHA and Oxidative Vulnerability
DHA's six double bonds make it highly susceptible to lipid peroxidation:
- Oxidative damage: Free radicals β DHA peroxidation β 4-hydroxyhexenal (4-HHE), malondialdehyde (MDA) β cellular toxicity
- Antioxidant protection required: Vitamin E (Ξ±-tocopherol), Vitamin C, glutathione, CoQ10, Astaxanthin
- Clinical implication: DHA supplementation without antioxidant support may paradoxically increase oxidative stress in high-oxidative environments (e.g., metabolic syndrome, smoking)
ΒΆ Clinical Significance
ΒΆ Evolutionary and Metabolic Context
DHA is essential but not efficiently synthesized by humans β ALA-to-DHA conversion is <1%, making it a "conditionally essential" fatty acid. This reflects evolutionary adaptation: ancestral diets rich in seafood and aquatic resources provided abundant preformed DHA, reducing selective pressure to maintain efficient endogenous synthesis. Modern Western diets (low fish, high processed foods) create an evolutionary mismatch β brain structure and function evolved expecting high DHA availability, but current intake is ~100 mg/day versus optimal 250-1000 mg/day.
ΒΆ Relevance to Metamodels
Metamodel 0 (Evolutionary Expectations): DHA is expected as a dietary staple; deficiency is a modern mismatch driving cognitive decline, depression, and impaired inflammation resolution.
Metamodel 1 (Selfish Systems): The selfish brain prioritizes DHA uptake via MFSD2A transporters, but chronic deficiency forces metabolic trade-offs β reduced synaptic DHA β impaired neurotransmission, membrane rigidity, reduced neuroplasticity.
Metamodel 3 (Regulation Disturbances): DHA deficiency impairs inflammation resolution β without D-series resolvins and maresins, acute inflammation becomes chronic low-grade inflammation (metaflammation). This underlies metabolic syndrome, cardiovascular disease, autoimmune diseases, and depression.
Metamodel 5 (Chronic Latent Acidosis): High omega-6:omega-3 ratios (typical Western ratio 15-20:1 versus optimal 4:1) drive pro-inflammatory eicosanoid production from arachidonic acid, exacerbating chronic inflammation.
ΒΆ Patient Populations and Conditions
Neurological/Psychiatric:
- Depression: Low DHA correlates with depression severity; RBC DHA
% predicts poor SSRI response. Supplementation (1-2 g/day EPA+DHA, ratio 2:1 EPA:DHA) shows efficacy equivalent to low-dose SSRIs in mild-moderate depression. - ADHD: DHA deficiency linked to attention deficits, impulsivity; supplementation improves reading, behavior in children (500-1000 mg/day).
- Alzheimer's Disease: Low plasma DHA predicts cognitive decline; DHA supports amyloid clearance, reduces tau pathology, enhances synaptic function. Intervention most effective in early stages (MCI).
- Cognitive function: DHA critical for working memory, processing speed, executive function; deficiency accelerates age-related cognitive decline.
Inflammatory Conditions:
- Rheumatoid arthritis: DHA-derived resolvins (RvD1, RvD3) reduce joint inflammation, pain, morning stiffness; fish oil (2-3 g EPA+DHA/day) shows clinical benefit.
- Inflammatory bowel disease: Maresins promote intestinal epithelial repair; DHA supplementation reduces relapse rates in Crohn's disease.
- Asthma: Protectin D1 reduces airway hyperresponsiveness, eosinophil infiltration; low DHA intake predicts asthma severity.
Cardiovascular:
- Triglyceride reduction: DHA lowers plasma triglycerides 20-30% (dose-dependent, 2-4 g/day) via β hepatic VLDL synthesis, β fatty acid oxidation
- Arrhythmia: DHA stabilizes cardiac myocyte membranes, reduces sudden cardiac death risk
- Atherosclerosis: Resolvins reduce plaque inflammation, promote regression
Pregnancy and Development:
- Fetal brain development: Third trimester demands 50-70 mg DHA/day for fetal brain growth; maternal deficiency β reduced offspring IQ, visual acuity, cognitive performance
- Postpartum depression: Maternal DHA depletion (β transfer to fetus) correlates with PPD risk; supplementation 800-1000 mg/day reduces incidence
ΒΆ Clinical Biomarkers
Omega-3 Index: RBC membrane EPA+DHA as % of total fatty acids
- Optimal: >8% (associated with lowest cardiovascular mortality, cognitive protection)
- Intermediate: 4-8%
- High-risk: <4% (increased inflammation, CVD risk, depression risk)
DHA:AA Ratio: Reflects balance between pro-resolving (DHA) and pro-inflammatory (AA) substrates
- Optimal: >1:1
- Typical Western: 1:10 to 1:20 (pro-inflammatory)
ΒΆ Intervention Implications
Supplementation Protocols:
- General health: 250-500 mg EPA+DHA/day (combined)
- Cognitive/mood disorders: 1-2 g/day (EPA:DHA ratio 2:1 for depression, 1:2 for cognitive decline)
- Inflammatory conditions: 2-3 g/day
- Pregnancy/lactation: 300-600 mg DHA/day
- Quality matters: Triglyceride or phospholipid forms > ethyl ester forms (better absorption); third-party testing for oxidation (TOTOX <26), heavy metals, PCBs
Dietary Sources (DHA per 100g):
- Salmon (wild): 1,400-2,000 mg
- Mackerel: 1,100-1,800 mg
- Sardines: 1,000-1,500 mg
- Herring: 1,200 mg
- Algal oil capsules: 200-400 mg/capsule (vegetarian/vegan option)
Synergistic Interventions:
- Antioxidants: Vitamin E (200-400 IU/day), astaxanthin (4-8 mg/day) protect DHA from oxidation
- Reduce omega-6 intake: Limit linoleic acid from vegetable oils (soybean, corn, sunflower) to improve omega-6:omega-3 ratio
- Aspirin: Low-dose aspirin (75-100 mg/day) promotes aspirin-triggered resolvin formation (AT-RvD1) β consider in high-inflammation states
Cautions:
- Bleeding risk: DHA (>3 g/day) has mild anticoagulant effects; monitor in patients on warfarin, antiplatelet agents
- Oxidation: Liquid fish oil prone to rancidity; store refrigerated, consume within 3 months of opening
- Contaminants: Choose molecularly distilled, third-party tested products (Nordic Naturals, Carlson Labs, Vital Choice)
ΒΆ Key Facts
- DHA comprises 40% of polyunsaturated fatty acids in the brain and 60% in retinal photoreceptors
- 60% of brain dry weight is lipid, with DHA as a dominant structural component
- Conversion efficiency from ALA to DHA is <1% in humans due to delta-6 desaturase rate-limitation and linoleic acid competition
- MFSD2A transporter is essential for DHA transport across the blood-brain barrier; mutations cause microcephaly
- Optimal omega-3 index is >8% (RBC EPA+DHA as % of total fatty acids); Western populations average 3-5%
- Western average DHA intake is ~100 mg/day versus recommended 250-500 mg/day (2-5Γ deficiency)
- DHA produces D-series resolvins (RvD1-6), protectins (PD1), and maresins (MaR1-2) via 15-LOX and 12-LOX pathways
- Pregnancy increases maternal DHA requirements by 50-70 mg/day for fetal brain development; deficiency predicts postpartum depression
- Low DHA (% omega-3 index) predicts poor SSRI response in depression and accelerates cognitive decline in aging
- Aspirin-acetylated COX-2 produces aspirin-triggered resolvins (AT-RvD1, AT-RvD3) with potent anti-inflammatory and pro-resolving actions
- DHA's six double bonds make it highly vulnerable to lipid peroxidation; antioxidant co-supplementation is essential
- Typical Western omega-6:omega-3 ratio is 15-20:1 versus optimal 4:1, driven by high linoleic acid intake
ΒΆ Connections
- omega-3 fatty acids β DHA is the longest-chain omega-3 PUFA and most metabolically active in the brain
- EPA β eicosapentaenoic acid is the precursor for DHA synthesis and produces E-series resolvins
- resolvins β DHA is the direct precursor for D-series resolvins (RvD1-6) that actively resolve inflammation
- protectins β DHA produces neuroprotectin D1 (PD1) via 15-LOX, essential for neuronal survival and synaptic plasticity
- maresins β DHA is metabolized by 12-LOX to maresins (MaR1-2), which promote tissue regeneration and efferocytosis
- 15-LOX β 15-lipoxygenase converts DHA to 17-HpDHA, the precursor for resolvins and protectins
- 12-LOX β 12-lipoxygenase converts DHA to 14-HpDHA, the precursor for maresins
- phospholipase A2 β PLA2 releases DHA from membrane phospholipids during inflammatory signaling, making it available for SPM synthesis
- arachidonic acid β DHA competes with AA for membrane incorporation and enzyme substrates; high DHA displaces AA, reducing pro-inflammatory eicosanoids
- inflammation resolution β DHA-derived SPMs are the primary mediators of active resolution; deficiency leads to chronic low-grade inflammation
- lipid mediator class switching β DHA enables the switch from pro-inflammatory lipoxins and prostaglandins to pro-resolving resolvins and maresins
- neuroplasticity β DHA supports synaptic membrane fluidity, receptor function, and BDNF signaling essential for learning and memory
- BDNF β DHA increases BDNF expression via CREB activation and epigenetic modifications, promoting neurogenesis and synaptic plasticity
- depression β Low DHA levels (% omega-3 index) predict depression severity and poor treatment response; supplementation shows antidepressant effects
- cognitive function β DHA is essential for working memory, processing speed, executive function; deficiency accelerates cognitive decline and Alzheimer's risk
- cardiovascular disease β DHA reduces triglycerides, arrhythmia risk, and atherosclerotic plaque inflammation; optimal intake lowers CVD mortality 30-40%
- blood-brain barrier β DHA crosses BBB via MFSD2A transporter as lysophosphatidylcholine-DHA; transporter deficiency causes microcephaly
- pregnancy β Maternal DHA is critical for fetal brain and retina development; deficiency predicts lower offspring IQ and postpartum depression
- omega-6 to omega-3 ratio β Western diets have 15-20:1 ratios (pro-inflammatory) versus optimal 4:1; increasing DHA intake improves balance
- oxidative stress β DHA's six double bonds make it vulnerable to lipid peroxidation; requires vitamin E, glutathione, and astaxanthin for protection
- linoleic acid β High LA intake (from vegetable oils) suppresses delta-6 desaturase, reducing ALA-to-DHA conversion and displacing DHA from membranes
- fish oil β Primary dietary source of preformed DHA; molecular distillation removes contaminants while preserving bioactivity
- Alzheimer's Disease β Low plasma DHA predicts cognitive decline; DHA supports amyloid clearance, reduces tau pathology, enhances synaptic function
- metabolic syndrome β DHA improves insulin sensitivity, reduces hepatic steatosis, lowers triglycerides; deficiency worsens metaflammation
- rheumatoid arthritis β DHA-derived resolvins (RvD1, RvD3) reduce joint inflammation, pain, and morning stiffness in RA patients
- inflammatory bowel disease β Maresins promote intestinal epithelial repair; DHA supplementation reduces relapse rates in Crohn's disease
- asthma β Protectin D1 reduces airway hyperresponsiveness and eosinophil infiltration; low DHA intake predicts asthma severity
ΒΆ Module References
- Module 5